How many times are you going to watch a project blow up and say, “I should’ve gotten in earlier”? Injective Protocol was one of those rare projects that slipped through the cracks for a lot of early adopters. Its early-stage price was laughably low compared to where it stands now—and those who caught the wave are chilling on massive profits. But if you’re still clinging to the regret of skipping out on Injective’s early momentum, there’s no point in drowning in what-ifs. What you really need is a smart way forward, something fresh, promising, and on the brink of making waves in 2025. The market doesn’t pause for regrets—it rewards the ones who move before the crowd wakes up.